Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

rred costs - - 55,055

Leasehold inducements (10,372) (10,371) (76,896)

Loss on disposal of equipment - - 23,532

Write-off of leasehold

improvements - - 86,349

Write-off of receivable 42,109 - 42,109

Leasehold inducement - - 89,148

Non-cash stock-based

compensation 696,818 224,036 2,497,496

Accretion of convertible

debentures - - 429,905

Loss on extinguishment of

debt - - 782,143

Services received for common

shares - - 400,024

Write-off of investment - - 20,000

Interest expense paid in

common shares - - 140,032

Change in non-cash operating

working capital items 109,584 549,700 4,388,693

-----------------------------------------------------------------------

(2,883,805) (2,187,703) (28,590,883)

Financing activities:

Issue of shares, warrants and

units, net of issuance costs 305,486 - 38,587,264

Issuance of convertible bridge

loan, net - - 2,196,619

Repayment of convertible bridge

loan, including costs - - (2,408,886)

Exercise of compensation

warrants - - 1,706,027

Exercise of stock options 118,825 153,917


'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The wet ... use of special anti-vascular endothelial growth factor agents given by injection into the ... not have a scientific protocol for the many millions diagnosed with it. AMD ...
(Date:9/2/2015)... , Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report "Gene ... offering. The markets for gene therapy are ... gene therapy product and it is marketed in ... are estimated for the years 2014-2024. The estimates are ...
(Date:9/2/2015)... 2, 2015 Biovista Inc. is ... the 2015 BeHEARD science challenge, a global competition hosted ... researchers, access to the latest life science innovations and ... and pathway analytics capability to support Steven Laffoon ... the study of Niemann-Pick Disease Type A (NPA), a ...
(Date:9/2/2015)...  Neurotech Pharmaceuticals, Inc., announced today the first ... 2 clinical trial of NT-503 Encapsulated Cell Therapy ... choroidal neovascularization secondary to age related macular degeneration ... growth factor (VEGF) receptor protein continuously produced by ... proof-of-concept study will evaluate NT-503 ECT as a ...
Breaking Biology Technology:StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Biovista Sponsors Wylder Nation Foundation's Research on Acid Sphingomyelinase Deficiency 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... Inc., an emerging biopharmaceutical company focusing on the development ... Simcere Pharmaceutical Group (NYSE: SCR ), a ... Drug (IND) application with the State Food and Drug ... as BD0801) as a potential cancer therapy.  APX003 is ...
... Netsmart Technologies, Inc., a leading provider ... organizations, today announced that its CMHC/MIS 4.2 electronic health ... testing for the 21 ARRA certification tests for which ... for 19 General and Ambulatory ...
... March 10, 2011 Volcano Corporation (Nasdaq: ... intravascular diagnosis and therapy guidance tools designed to enhance ... today that it will be participating in the Roth ... March 14. The presentation by David Sheehan, ...
Cached Biology Technology:Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND 2Netsmart Technologies' CMHC/MIS Behavioral Health Software Passes ARRA Certification Tests 2Netsmart Technologies' CMHC/MIS Behavioral Health Software Passes ARRA Certification Tests 3Netsmart Technologies' CMHC/MIS Behavioral Health Software Passes ARRA Certification Tests 4
(Date:8/6/2015)... , Aug. 6, 2015 Synaptics Inc. ... human interface solutions, today announced collaboration with Microsoft ... Windows 10. Microsoft leveraged Synaptics, deep expertise in ... system. Through stringent testing, Synaptics, ... certified with Microsoft,s Precision TouchPad (PTP) specification empowering ...
(Date:8/5/2015)... 2015 The biosensors market is proving highly ... into newer sectors, and development of devices resulting in ... has seen the entry of multiple participants each year ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... the Global Biosensors Market ( http://www.frost.com/nee9 ), finds ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... action that leads to a greener future, according to new ... the Association for Psychological Science. The research, conducted ... Bang and Elke U. Weber of Columbia University, suggests that ... the long life expectancy of a nation, and not necessarily ...
... the Negev (BGU) signed a Memorandum of Understanding with ... Group of China, to create the Kubuqi Desert Research ... Kubuqi institute is to develop China,s desert economy in ... recognized for its research in desert agriculture, alternative energy ...
... of cholesterol functions like the hormone estrogen to fuel the ... cancers, researchers at the Duke Cancer Institute report. The ... to diminish the effect of this estrogen-like molecule. Published ... Science , the findings are early, using mouse models and ...
Cached Biology News:To boost concern for the environment, emphasize a long future, not impending doom 2Ben-Gurion University of the Negev to collaborate with Chinese company to create Kubuqi Desert Research Institute 2High cholesterol fuels the growth and spread of breast cancer 2
... membrane filters suitable for use in the Microsart ... of each filter, in a specially designed individual ... pleating of the band of membrane filter units ... The shape of the sealed band guarantees uniform ...
...
... PC, is used to perform runs ... from the Experion automated electrophoresis system. ... and simulated gel views and summarizes ... a Results table. This software is ...
... rolled steel with stove enamel coated (RAL 7035 ... Front, back and side windows ... lamps Internal adjustable tempered glass shelf ... Lighting 600 lux ...
Biology Products: